(Q34380965)

1 August 2017

1 reference

title

Disorders of prolactin secretion. (English)

1 reference

1 August 2017

Molitch ME

1

1 reference

1 August 2017

publication date

1 September 2001

1 reference

Endocrinology and Metabolism Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

30

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

585-610

1 reference

Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Vasoactive intestinal polypeptide is synthesized in anterior pituitary tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Abnormal transduction mechanisms in pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Neurogenic Galactorrhea-Amenorrhea*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Surgery during pregnancy and fetal outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Prolactinomas and resistance to dopamine agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Bromocriptine as prophylactic therapy in prolactinoma during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Tumour suppressor genes in the pathogenesis of human pituitary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Treatment of macroprolactinoma with cabergoline: a study of 85 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Transforming DNA Sequences Present in Human Prolactin-Secreting Pituitary Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

A prolactin-releasing peptide in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Serum prolactin levels in untreated primary hypothyroldism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Vaginal bromocriptine in hyperprolactinemic patients and puerperal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Long-term follow-up of patients with hyperprolactinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Hyperprolactinemia. Long-term effects of bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Prolactin release by vasoactive intestinal polypeptide in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Increased circulating levels of bromocriptine after vaginal compared with oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Reduction in size of prolactin-secreting tumours in men treated with pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Bromocriptine in pregnancy: safety aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Perivascular fibrosis in prolactinomas: is it increased by bromocriptine?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine☆

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

1 reference

7 January 2021

Increased Prolactin Levels During Reserpine Treatment of Hypertensive Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

The natural history of idiopathic hyperprolactinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pathogenesis of pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pituitary incidentalomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Is prolactin secreted ectopically?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Serum prolactin in liver disease and its relationship to gynaecomastia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Current approaches to imaging of the sellar region and pituitary

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Resistance to bromocriptine in prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pit-1 gene expression in human pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pituitary carcinoma: a clinicopathologic study of 15 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Management of extra-sellar pituitary tumours with bromocriptine: comparison of prolactin secreting and non-functioning tumours using half-field visual evoked potentials and computerised tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Ergot-induced inhibition of pituitary tumor growth in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Follow-up of children born of bromocriptine-treated mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pregnancy in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Vasoactive intestinal polypeptide: Release into hypophyseal portal blood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

The natural history of untreated hyperprolactinemia: a prospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

The natural history of untreated microprolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Elevation of plasma-prolactin by monoamine-oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Effects of methyldopa on prolactin and growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Two-year treatment with oral contraceptives in hyperprolactinemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Rapid regression of pituitary prolactinomas during bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Rapid Changes of Prolactinoma Volume after Withdrawal and Reinstitution of Bromocriptine*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Role of radiation therapy in clinical hormonally-active pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

CV 205-502 treatment of hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Natural history of microprolactinomas: six-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Bromocriptine treatment of prolactin-secreting tumors: surgical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

Pituitary Tumor Transforming Gene (PTTG) Expression in Pituitary Adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970203-6

7 January 2021

10.1016/S0889-8529(05)70203-6

Identifiers

DOI

1 reference

1 August 2017

1 reference